Stockscreener 앱 받기
0.8201
2.37%
-0.0199
전일 마감가:
$0.84
열려 있는:
$0.84
하루 거래량:
239.72K
Relative Volume:
0.36
시가총액:
$25.91M
수익:
$1.22M
순이익/손실:
$-22.43M
주가수익비율:
-0.7092
EPS:
-1.1564
순현금흐름:
$-18.78M
1주 성능:
+6.35%
1개월 성능:
+21.30%
6개월 성능:
+48.78%
1년 성능:
-32.22%
1일 변동 폭
$0.8157
$0.865
1주일 범위
$0.7624
$0.865
52주 변동 폭
$0.475
$1.80
Longeveron Inc Stock (LGVN) Company Profile
명칭
Longeveron Inc
전화
305-302-7158
주소
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.8201 | 25.91M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
Longeveron Inc 주식(LGVN)의 최신 뉴스
Longeveron’s Alzheimer’s trial data accepted for poster presentation - Investing.com
Longeveron to Present Additional Phase 2a Laromestrocel Data in Mild Alzheimer’s Disease at AAIC 2026 - Quiver Quantitative
Longeveron gets AAIC poster slot for Alzheimer’s stem cell data - Stock Titan
Longeveron Inc (LGVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Longeveron Inc (LGVN) Institutional Confidence - TradingKey
Longeveron Inc (LGVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Longeveron Inc (LGVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Longeveron Inc (LGVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Longeveron Inc (LGVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Longeveron Inc (LGVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Longeveron Inc (LGVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Longeveron Inc (LGVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Longeveron receives SME status from European regulator By Investing.com - Investing.com Nigeria
Longeveron receives SME status from European regulator - Investing.com UK
Longeveron Granted SME Status by European Medicines Agency - Moomoo
Longeveron Inc. Awarded SME Status by European Medicines Agency, Enhancing Drug Development Opportunities - Quiver Quantitative
Biotech Longeveron wins EMA SME status, where SME drugs saw 89% OKs - Stock Titan
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Number of shareholders of Longeveron Inc. – BOATS:LGVN - TradingView
LGVN Q1 2026 Earnings: Deeper Losses Weigh on Shares as Clinical Progress ContinuesGross Profit Margin - newsline.com
Longeveron Announces CFO Transition to Internal Successor - TipRanks
LongeveronOn June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor - Stock Titan
Longeveron to Present at BIO International Convention 2026 - BioSpace
LGVN Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D AdvancesCapex Guidance - newsline.com
LGVN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Clinical-Stage Biotech Navigates Costs - newsline.com
Longeveron Inc. (LGVN) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Trend Analysis - The Legal Advocate
Longeveron (LGVN) Stock Forecast & Analyst Ratings - Moomoo
LGVN | Longeveron Inc. Common Stock Executive Compensation - Quiver Quantitative
Longeveron Inc. Q1 2026 Earnings: EPS Misses Estimates Despite Stock RallyAdjusted Earnings Analysis - newsline.com
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN
LGVN Should I Buy - Intellectia AI
Longeveron CEO outlines strategy ahead of August trial data - Investing.com India
Longeveron CEO outlines strategy ahead of August trial data By Investing.com - Investing.com Nigeria
Longeveron Inc. (LGVN) Edges Higher Amid Stabilization at $0.72Dividend Growth Stocks - The Legal Advocate
[ARS] Longeveron Inc. SEC Filing - Stock Titan
Longeveron (NASDAQ: LGVN) plans reverse split, bigger share pool and incentive plan - Stock Titan
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering ... - Caledonian Record
Longeveron Issues Letter to Stockholders Highlighting - GlobeNewswire
Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model - MSN
Inside Longeveron’s stem-cell push on a deadly infant heart defect - Stock Titan
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift By Investing.com - Investing.com Nigeria
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift - Investing.com
Longeveron Inc (LGVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):